Findings showed 67% of the omalizumab group achieved the primary endpoint compared with 7% of the placebo group. Treatment with omalizumab, an anti-IgE antibody, significantly increased the amount of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results